5:45 PM
Jul 02, 2009
 |  BC Extra  |  Clinical News

Lundbeck meets Phase II depression endpoint

H. Lundbeck A/S (CSE:LUN) said top-line results from a Phase II trial to treat major depressive disorder showed 5, 10 and 20 mg...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >